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The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral genome sequences,
especially in the viral envelope (Env160). Since it is not possible to directly match the vaccine strain to the vast
number of circulating HIV-1 strains, it is necessary to develop an HIV-1 vaccine that can protect against a
heterologous viral challenge. Previous studies from our group demonstrated that a mixture of wild type clade B
Envgp160s were able to protect against a heterologous clade B challenge more effectively than a consensus clade B
Envgp160 vaccine. In order to broaden the immune response to other clades of HIV, in this study rhesus macaques
were vaccinated with a polyvalent mixture of purified HIV-1 trimerized consensus Envgp140 proteins representing
clades A, B, C, and E. The elicited immune responses were compared to a single consensus Envgp140 representing all
isolates in group M (Con M). Both vaccines elicited anti- Envgp140 IgG antibodies that bound an equal number of
HIV-1 Envgp160 proteins representing clades A, B and C. In addition, both vaccines elicited antibodies that
neutralized the HIV-1SF162 isolate. However, the vaccinated monkeys were not protected against SHIVSF162p4
challenge. These results indicate that consensus Envgp160 vaccines, administered as purified Envgp140 trimers, elicit
antibodies that bind to Envgp160s from strains representing multiple clades of HIV-1, but these vaccines did not
protect against heterologous SHIV challenge.Introduction
One of the greatest struggles for developing a preventative
human immunodeficiency virus (HIV)/acquired immuno-
deficiency syndrome (AIDS) vaccine is overcoming the
diversity of viral isolates [1]. The Envgp160 sequences can
differ up to 35% between clades and ~15% within a spe-
cific clade [2]. Viruses classified as clade B are responsible
for ≥40% of infections in the Americas and Europe, but in
Asia and sub-Saharan Africa, where most new infections
are recorded each year, other clades are dominant. Most
new infections in these regions are classified as clades A,
C, or A/E viruses [1,3]. Any HIV vaccine that will prevent
infection must be able to overcome the diversity of HIV
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reproduction in any medium, provided the orTo overcome the HIV sequence diversity, polyvalent
mixture of antigens and consensus proteins were designed
[4-7]. Polyvalent vaccines increase breadth by including
multiple copies of a target (s) or epitopes into a single for-
mulation. Polyvalent vaccine strategies have been employed
to increase the breadth of the humoral and cellular
immune responses [8,9]. Polyvalent mixtures of Envgp140 or
HIV proteins (Gag-Pol, Tat and trimeric Envgp140) elicit a
degree of protection against heterologous challenge [8,10].
Consensus-based vaccines rely on a centralized antigen
designed to reduce sequence diversity by using the most
common amino acid at each position of the protein. Con-
sensus vaccines are designed to reduce the genetic differ-
ences between the vaccine and the primary isolate and
increase the breadth of immune responses [11-14].
To overcome the diversity in Envgp160 sequences and to
design a more effective AIDS vaccine, consensus Envgp140
sequences were designed for 4 clades of HIV-1 (A, B, C,
and E), as well as a single consensus Envgp160 representing
isolates from all of Group M. For the first time, in thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were used in a polyvalent vaccine mixture, and compared
to a Con M Envgp160, to assess the ability to elicit a broadly
reactive anti-Envgp160 immune response. The immuno-
logical responses of the polyvalent mixture in vaccinated
rhesus macaques were compared to that of the single Con
M Envgp140 vaccine. Both vaccines elicited anti-Env im-
mune responses against multiple clades of HIV; however
neither vaccine strategy efficiently protected monkeys
against a SHIVSF162p4 challenge.
Results
Characterization of consensus envelopes
The goal of this study was to design a HIV Envgp160 vac-
cine that elicits broadly reactive immune responses in an
effort to overcome the inherent diversity in the Envgp160.
Therefore, an HIV-1 group M consensus Envgp140 vaccine
was compared to a polyvalent mixture of clade consensusFigure 1 Characterization of consensus Envgp140s. A) 1 μg of each puri
stained. The top of the gel is labeled with the consensus Envgp140 present
B) Using surface plasmon resonance, the interaction of the consensus Envg
association between b12 and the Envgp140 and the y-axis gives the dissocia
indicated by the darker symbols on the graph and the primary envelope tr
and negative control BSA was pre-incubated with Histag soluble human CD
incubated with the anti-his antibody. Using immunoprecipitation (IP), sCD4
Supernatants and pellet fraction was analyzed by SDS-PAGE and western b
supernatants fraction. Right panel: pellet fraction (sCD4 and proteins bound
with rabbit polyclonal anti- Envgp160 antibody and the bottom blots were p
IgG, SouthernBiotech). Lane 1: BSA, Lane 2: Con M Envgp140, Lane 3: Consen
Envgp140, Lane 6: Consensus A Envgp140.Envgp140s representing 4 individual clades of HIV-1 (A, B,
C, and E). The env gene sequences were then truncated at
the transmembrane domain, and the cleavage site mutated,
to generate a Envgp140 [15]. To stabilize the truncated
Envgp140 trimers, the bacteriophage fibronectin domain
(FT) was added to the 3’ end of the Envgp140 sequence, as
previously described [15].
Purified trimerized Envs were detected at ~480kDa size
indicating oligomerization as trimer proteins (Figure 1A).
Some Env dimers were observed in consensus C, E and M
Envgp140 protein fractions. To probe the antigenic struc-
ture, the broadly reactive monoclonal antibody b12 [16]
was used to determine binding kinetics to each consensus
envelope by surface plasmon resonance (SPR) on a Biacore
3000 (Figure 1B and Additional file 1: Figure S1). The rate
of association between the consensus Envgp140 trimers and
b12 was similar to the rate of association between b12 and
primary Envgp140 trimers. The rate of dissociation of b12fied consensus Envgp140 was loaded onto a native PAGE and then sliver
in the lane and the protein ladder values are present on the y-axis.
p160s and b12 was investigated in solution. The x-axis gives the rates of
tion between the Envgp160s and b12. The consensus trimers are
imers are indicated by the lighter symbols. C) The consensus Envgp140s
4 at 37°C then mixed in with magnetic beads that were pre-
and anything bound to it was pulled down in the pellet fraction.
lot using anti-his and anti- Envgp160 antibodies. Left panel:
). The protein ladder values on y-axis. The upper blots were probed
robed with mouse anti-human CD4 antibody (Clone RFT-4g mouse
sus E Envgp140, Lane 4: Consensus C Envgp140, Lane 5: Consensus B
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sensus B, which had a slower rate of disassociation. Each
Envgp140 bound to the primary HIV receptor, human CD4
(hCD4) (Figure 1C). The MAb b12 is a monoclonal isolated
from an infected patient with a consensus B wild-type
Envgp160 on its viral surfaces and therefore may recognize
clade B Envgp160 with more efficiency than non-clade B
Envgp160s. In addition, consensus B envelopes are bound
with higher affinity antibodies to clade B Envgp160s, but less
so with consensus C Envgp140. The reverse is true as well. A
polyclonal serum, HIV-Ig, was obtained from the AIDS
Reference and Reagent Program. This polyclonal serum,
collected from a clade B infected person, may not recognize
the consensus E Envgp160 with the same affinity and effi-
ciency as the consensus B Envgp160.
Vaccination of non-human primates with consensus
envelopes
To determine the ability of the vaccines to induce a
protective response in non-human primates, rhesus ma-
caques were vaccinated intramuscularly with 300 μg of
total Envgp140 protein either Con M or the polyvalent
Con Mixture (equal amounts of each Envgp140 protein).
Animals were treated according to the guidelines of the
IACUC of the University of Pittsburgh. All the protocols
used were approved by the IACUC of the University of
Pittsburgh (#1002617). Monkeys were administered 3
vaccinations of Envgp140 formulated with Imject
W alum
adjuvant. Mock vaccinated monkeys were administered
PBS formulated with adjuvant (Table 1). Monkeys vacci-
nated with Con M or polyvalent consensus developed anti-
Envgp140 antibody titers greater than 1:400 dilution against
all consensus Envgp160s following the three vaccinations
(Figure 2A). Collected sera were tested for the ability to
bind to a set of primary Envgp160s representing clades A, B,
C, and E (Table 2). The diversity of the Envgp160s chosen, as
well as their similarity to the consensus Envgp160s, is
displayed in the phylogenetic tree where Envgp160s cluster
into their identified clades (Figure 2B). The Con M did not
cluster with any one clade, but as expected, was located in
a more central position on the tree.
Both Con M and polyvalent consensus Envgp140 vac-
cines elicited anti- Envgp140 antibodies that recognized
Envgp160s from clade A, B and C. However, the Envgp160
SC42, THRO4, PVO4, (clade B), DU172 (clade C) andTable 1 Vaccine groups and regimen of non-human primate s
Vaccine group Animal numbers Vacc
Group 1 N1,N2,N3,N4 Adjuv
Group 2 P1,P2,P3,P4 Mixtu
Group 3 M1,M2,M3,M4 Con
Each animal was vaccinated 3 times week 0, 4 and 8. Each vaccine was given in com
the identification number of animals in each group and the vaccine and treatment93TH975 (clade E) were not significantly recognized by
sera collected from vaccinated animals (Figure 2C).
Overall, there was no binding preference of the elicited
anti-Envgp160 antibodies to primary Envgp160s based on
clade, location, or year of Envgp160 isolation.
SHIVSF162p4 challenge
To evaluate the protective efficacy of each vaccine, mon-
keys were challenged rectally four weeks after final vacci-
nation with SHIVSF162p4 (dose: 640TCID50) to ensure all
mock vaccinated animals become infected. All mock vac-
cinated and polyvalent consensus vaccinated monkeys
were infected following challenge (Figure 3A and B). Viral
loads peaked at day 14 post-challenge at ~1 × 10e+6 RNA
copies/ml and then declined to undetectable levels by day
80 post-infection as seen in previous studies using the
same stock of virus (unpublished and [8]. Two out of four
monkeys (M1 and M4) vaccinated with Con M vaccine
had no detectable virus at any time point post-challenge
(Figure 3C). Monkeys M2 and M3 had a similar viral
pattern as mock vaccinated monkeys with a peak at day
14, followed by a rapid decline.
To determine whether Con M Envgp140 vaccinated
monkeys were protected from infection, at day 70 post-
challenge all Con M Envgp140 vaccinated monkeys were
depleted of CD8+ cells by administering monoclonal
antibody M-T807R1 intravenously [17]. Seven days fol-
lowing antibody administration, no CD8+ cells were
detected in the peripheral blood that was sustained for
an additional 18 days (Figure 4A). Previously infected
monkeys M2 and M3 had a re-emergence of virus du-
ring this CD8+-depletion period (Figure 4B). Monkey
M4 who was initially aviremic after challenge had an
emergence of virus after CD8+-depletion. In contrast,
monkey M1 maintained undetectable viral loads follo-
wing CD8+ depletion.
Responses to the challenge envelope SF162
At 2 weeks after final vaccination (day -14 prior to cha-
llenge), anti-EnvSF162 IgG antibodies were detected in
monkeys vaccinated with either vaccine (Figure 2C). In
addition, these antibodies were able to neutralize the
ability of HIVSF162 to infect cells in vitro (Figure 5A).
The presence of neutralization titers to all Envgp160s used
in the ELISA binding assay were investigated, however,tudy
ine given Other treatment
ant only
re of Con A,B,C,E Env gp140
M Env gp140 Depletion of CD8+ T cells
bination alum imject© as an adjuvant. The table gives the vaccine groups,
(in the case of group 3) received by the animals.
Figure 2 Binding breadth of vaccinated NHPs sera. NHP were vaccinated at weeks 0, 4 and 8 with blood collected 14 days after each
vaccination. Vaccines were formulated with 300 μg of purified protein and ImjectW alum and delivered intramuscularly. A) Sera collected on day
35 was pooled and used to determine total IgG via ELISA for each vaccine group. Bar values represent the geometric mean titer
(+95% confidence interval) of log2 transformed titers. The endpoint titer is described on the y–axis and the identified Envgp140 trimer antigen is
described on the x-axis. B) The unrooted phylogenetic tree was produced using Phylogeny.fr web service and the 14 HIV-1 Envgp160 sequences
based upon the list of Envgp160s in Table 2 showing. The Envgp160s were from clades A, B, C, E from 1993-2005. The clades are indicated on the
tree and the consensus Envgp160s are circled. C) At day 35 post-vaccination, anti-Envgp160 IgG was detected in the serum samples (1:100 dilution)
against a panel of primary Envgp120s from clades A, B, C and E via ELISA. Bar values represent the geometric mean titer (95% confidence interval)
at an OD450. The OD450 values are displayed on the y-axis and the Envgp120s used are listed on the x-axis. A two-way ANOVA with Bonferroni’s
post-test was used to evaluate Statistical significance between the vaccines for each test antigen. A p-value of less than 0.05 was
considered significant.
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nated monkeys had a neutralizing titer of 1:40, except
for monkey M4 that had a titer of 1:320. Two weeks
following challenge, only monkey P4 had an increase in
neutralizing titers. There were detectable neutralization
titers in 3 of the 4 mock vaccinated monkeys two weeks
post-challenge (Figure 5A). No monkey had antibodies
that recognized a set of overlapping SF162 Envgp160 pep-
tides. These pools of peptides represented the SF162
Envgp160 regions V1/V2, V1 only, or V2 only (data not
shown). Interestingly, there was no detectable IFN-γ
Envgp160 or gag-specific T-cell responses prior to cha-
llenge or 7 days post-challenge. At day 14 and 21 post-
challenge, IFN-γ T cell responses were detected in all
monkeys (Figure 5B), with no significant differences in
the number of cells between groups.Discussion
HIV-1 Envgp160 based vaccines protect monkeys against a
homologous SHIV challenges [18,19]. The ability to match
the gene sequences used in the vaccine to the possible
exposure virus in humans is not possible. Therefore, stu-
dies that use a matched Envgp160 in the vaccine to the
challenge strain is appropriate for proof-of concept stu-
dies, but our group set a more challenging goal to protect
against a challenge virus with a mismatched vaccine with
a limited number of vaccinations. We report here that
each consensus sequence representing clade A, B, C, E, in
a polyvalent mixture or as a single consensus Envgp160
representing the entire Group M elicited anti-Envgp140
antibodies that bound to a broad panel of HIV-1
Envgp160s. The immunization schedule used was not opti-
mal for antibody affinity maturation; nonetheless, the
Table 2 Information of envelopes used for assays
Env ID Clade Location Mode of transmission Length of infection Mo/yr isolated Corecepter
Du172.17 C South Africa M-F 12 weeks Nov-98 R5
ZM214M.PL15 C Zambia F-M <13 weeks Jul-03 R5
CAP210.2.00.E8 C South Africa M-F 5 weeks May-05 R5
CHN19 C China R5
HIV16936-2 EF117270 C India F-M 1 week Nov-00 R5
Q168.ENV.B23 A Kenya M-F 1 week R5
Q461.ENV.C2 A Kenya M-F 4 weeks R5
HIV env 6235 clone 3 B USA M-M 6 weeks Mar-95 R5
PVO clone 4 B Italy M-M 4 weeks Jan-96 R5
pRHPA 4259 clone7 B USA M-F < weeks Dec-00 R5
pTHRO4156 clone 18 B USA M-M 1 week Aug-00 R5
SC 422661.8 B Trinidad F-M 4 weeks Jan-95 R5
SF162 B USA R5
93TH975-15 E Haiti F-M <18 weeks Jan-93 R5
Primary envelopes from various clade was chosen based to have a diversity of locations and mode of mocusal transmission. Envelopes were used to test the
presence of binding and neutralizing antibodies elicited by vaccination of consensus vaccines in non-human primates. SF162 was included because it is the
challenge virus envelope.
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the challenge Envgp160. However, the elicited immunity
did not prevent infection by SHIVSF162p4.
In previous studies, consensus sequences designed for
clades B and C Gag and Envgp140 elicited increased
breadth of humoral and cellular immune responses
[12,20-22]. Consensus Envgp160 sequences representing
Group M, termed CON-S, elicited antibodies that
neutralized multiple Envgp160s, as well as eliciting cross-
clade cellular immune responses [13,14]. However, viral
challenges of CON-S vaccinated monkeys were not
reported and therefore the efficacy of the induced im-
mune response elicited by these vaccines is unknown.
Compared to Envgp120 monomers, Envgp140 trimers
may expose binding and neutralizing epitopes that are
present only in Env’s quaternary state [23,24]. Our con-
sensus Envgp140 trimers have similar antigenic properties
as wild-type Envgp160s, as demonstrated by attaching to
human CD4 and binding to the monoclonal antibody
b12. The b12 antibody recognizes a conserved region on
gp120 mapped to a discontinuous epitope overlapping
the CD4 binding site [25].
Following three intramuscular vaccinations, all monkeys
seroconverted by day 14 following the final vaccination.
Nonetheless, there were differences in the vaccine efficacy
following challenge between the two vaccine groups. Both
non-neutralizing and neutralizing antibodies have been
implicated in reducing rates of infection by HIV-1 [26,27].
A report based on the analysis of the sera samples of vac-
cinated volunteers in the RV144 clinical trial stated that
the vaccine elicited antibodies against the V2 region of the
HIV-1 Envgp160 were correlated with lower rates of HIVinfection [28]. Antisera collected from these vaccinated
individuals did not neutralize the infection in vitro. Add-
itionally, vaccine induced protection against a neutralization
resistant virus in macaques was correlated with antibodies
to the V2 region of Envgp160 [29]. Whether antibodies that
bind to the V2 region are correlated with protection against
SHIVSF162p4 infection in this study is unclear. There were
no antibodies elicited in monkeys vaccinated with Con M
or polyvalent consensus Envgp140 vaccines that recognized
SF162 Envgp160 linear peptides, including those specific to
V2 (data not shown). Further studies are necessary to de-
termine if the two protected animals in the Con M Envgp140
group elicited antibodies recognizing conformational epi-
topes, such as the V1/V2 scaffold proteins. The V1/V2
scaffold was used to analyze human sera collected from
vaccinated volunteers in the RV144 clinical trial [30,31].
Determining if antibodies specific to various conform-
ational epitopes on Envgp160 may explain the differences ob-
served in vaccinated animals following SHIV challenge.
Two monkeys that had no detectable viral levels follow-
ing SHIV infection were M1 and M4. M2 and M3 had
detectable viral levels and therefore were not protected
against infection. Monkeys vaccinated with either polyva-
lent consensus or Con M Envgp140 trimers had neutraliz-
ing titers to HIV-1SF162. Neutralizing antibodies against
Envgp160 can protect monkeys against viral challenge
[32,33]. However, only one monkey (M4) in the present
study had high neutralizing antibodies (1:320) against
SHIVSF162p4 and had undetectable viral titer 14 days after
challenge. However, following CD8+ T cell depletion, virus
was detected (<1×105 RNA copies /ml) in the blood indi-
cating that infection was not blocked, but may have been
Figure 3 Heterologous virus challenge. Monkeys were challenged rectally with 640 TCID50 SHIV SF162p4 at week 12 post initial vaccination. Viral
titers were determined from collected sera. Viral titers for each individual monkey are displayed as RNA copies/ml of blood on the y-axis by days post
challenge on the x-axis. A) Mock vaccinated animals (Imject© adjuvant only). B) Polyvalent Consensus Envgp140 vaccine C) Con M Envgp140 vaccine.
Eugene et al. Virology Journal 2013, 10:102 Page 6 of 11
http://www.virologyj.com/content/10/1/102controlled by the vaccine elicited antibodies. T cell
responses did not appear to play a role in protecting the
monkeys from infection. There was no difference in the
number or kinetics in the elicitation of Envgp160 or Gag spe-
cific IFNγ producing cells following challenge in any of the
vaccinated monkeys compared to mock vaccinated animals.
Upon CD8+ depletion, it was not unexpected that M2
and M3 had a rebound in blood titer virus, but the detec-
tion M4 was unexpected. In contrast to monkey M4, no
virus was detected in monkey M1 even after depletion of
CD8+ T cells. Both IFNγ specific T cells and neutralizing
antibodies were detected, but it is unclear which of these
immune responses may have contributed to the protec-
tion. In addition, the MHC class I haplotype did not ap-
pear to correlate with protection. Even though no viremia
was ever detected in monkey M1, it is possible that virus
could be located in reservoirs, such as the bone marrow
or gut mucosa [34]. The M-T807R1 monoclonal antibody
used for CD8+ T cell depletion is specific for cells in the
serum and lymph nodes [35], therefore, it may have not
depleted cells in reservoirs of hidden virus. In an effort to
identify possible reasons for M1 protection the animals’
halotypes were determined. Monkey M1 had a Mamu-B
*008 MHC class I haplotype, which has been associated
with control of SIVmac239 virus; the parent virus of thechallenge SHIVSF162p4 [36]. Therefore, a combination of
the neutralizing antibodies, non-neutralizing antibodies
and the Mamu-B*008 MHC class I haplotype may have
resulted in “sterilizing” protection after viral challenge.
However, the Mamu-B*008 MHC class I haplotype was also
present in monkey M3, which had similar binding and
neutralizing antibody titers as monkey M1, but was not
protected from SHIV infection. Interestingly, two monkeys
vaccinated with the polyvalent consensus vaccine, P2 and
P4, had a rebound in viral titers at day 40 post-infection
before returning to undetectable levels (Figure 3B). The
rebound virus could have been a variant that escaped the
vaccine elicited immune response, however, sequencing of
the virus in the blood collected at day 40, did not show any
significant variation of the viral sequence compared to the
input virus on day 0.
While Envgp140 only vaccines have been successful
against homologous challenge, both the human RV144
trial and previous monkey studies showed significant pro-
tection from heterologous challenge, included other HIV
protein components [8,37,38]. Including Tat in the vaccine
formulation induces strong and persistent CD4+ T cells
[39] and broadens T cell responses directed against Gag
and Envgp160 [40,41]. Gag is known for inducing strong
cellular responses that may lead to reduced viral loads
Figure 4 CD8+ T cell depletion. Animals vaccinated with Con M Envgp140 were all depleted of CD8+ cells by administering the M-T807R1 antibody
subcutaneously (50 mg/Kg) at day 0 (day 70 post challenge). A) Number of CD8+ cells following antibody administration over the 25 day period of
observation. B) Viral titers for each individual monkey are displayed as RNA copies/ml of blood on the y-axis by days post challenge on the x-axis.
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may have prevented infection or controlled undetectable
virus in vaccinated animals more effectively than Con M
Envgp140 alone. Even though some of these studies use
Envgp140 proteins, they are combined with other HIV
proteins to elicit a broadly reactive response. In our vac-
cine presented here, the purified VLPs only have Gag and
Envgp140 expressed in different modalities than VLPs and
we achieve a broadly reactive anti-Envgp140 response using
our consensus Envgp160s. For example, viral vectors are
used to express Gag and Envgp160 independently in the
RV144 human trial, which really does not allow for com-
parison with our VLP strategy.Conclusion
Rhesus macaques were vaccinated with trimerized Envgp140
proteins representing consensus sequences for clade A, B,
C, E, in a polyvalent mixture or as a single consensus
Envgp160 representing the entire Group M. These consen-
sus Envgp140 elicited antibodies with cross-clade anti-Env
gp140 binding against a panel of HIV-1 Envgp160s. However,




The consensus sequences represent the most common
amino acids found at each position of the aligned envelope
sequences used. One hundred Envgp160s sequences per
clade were used to design consensus sequences of clades
A, B, C, and E. The design of the group M consensus
Envgp160 was based on two hundred Envgp160 sequences
representing clades A, B, C, D, E, F and H. Envgp160s
chosen were isolated following mucosal transmission,
within weeks after infection and included a diversity of
viruses that were isolated in different locations around the
world between 1995 and 2005. Each Envgp160 used the
CCR5 co-receptor. Vaccine immunogens were designed as
Envgp140 trimers as previously described [15].
Protein purification
Human embryonic kidney (HEK) 293T cells were transi-
ently transfected with DNA (8 μg) expressing one of the
consensus HIV-1 Envgp140 proteins or wild type Envgp120
Figure 5 Neutralizing titers to the SF162 Envgp160 and post challenge cellular responses. A) Neutralization of HIVSF162 by serum collected
at day 21 and 35 post-vaccination and 14 post-challenge. The pooled sera dilution at which 50% of virus infection is inhibited is displayed on the
y-axis. Neutralizing titers for individuals monkeys are listed on the x-axis by each vaccine group. B) INF-γ ELISPOTs were performed using monkey
PBMCs collected 14 (left panel) and 21 (right panel) days post-challenge. 1x105 PBMCs were stimulated with 30 ug of Gag peptide pools
representing SIVmac239 or Envgp160 pools representing either Con M or SF162p3 (overlapping peptides, 15-mers with11 amino acid overlap NIH
AIDS Research and Reference Reagent program Env 211 peptides and Gag 125 peptides). Spot forming units (SFU) per one million PBMCs are
listed on the y-axis and the peptide pools are listed on the x-axis.
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previously described [44], secreted Envgp140 proteins were
purified using lectin columns made from agarose galanthus
nivalis (snowdrop) lectin (Vector laboratories, Burlingame,
CA, USA) [45] and the Envgp120 6X-HIS tagged proteins
were purified using nickel columns [44]. Other purified
Envgp160s used for ELISAs were purchased from eEnzyme
(Gaithersburg, MD, USA). Each purified consensus Envgp140
trimer protein (1 μg) was loaded on to NativePAGE native
gel (Invitrogen, Carlsbad, CA, USA) and separated by
electrophoresis in the manufacture’s recommended buffers.
After separation, the proteins were detected using the
ProteoSilver Sliver Stain kit (Sigma, St. Louis, MO, USA)
following manufacturer’s protocol [44].
CD4 binding assay
The CD4 binding assay was performed to demonstrate
Envgp160 binding to its primary receptor using a similar
protocol as previously described [46]. Protein G Dynabeads
(Invitrogen) were mixed with anti-his antibody. The tubes
with the mixture were placed on the magnets to removeall unbound antibody. Then soluble human CD4-6XHIS
tagged protein (eEnzyme, Gaithersburg, MD, USA) and
consensus Envgp140 mixtures were then mixed with the
beads. Following pellet fractionation, samples were sepa-
rated on a 10% SDS PAGE gel, transferred unto a nitrocel-
lulose membrane and probed for sCD4 or Envgp160 using
specific antibodies. Following secondary IgG-HRP anti-
bodies which were used to detect proteins by Western blot.
Surface plasmon resonance
MAb b12 binding kinetic analyses of the HIV rgp140(s)
was performed by surface plasmon resonance (SPR) on a
Biacore 3000 (GE/Biacore AB, Inc., Uppsala, Sweden) as
previously described [47].
Animals and vaccination
Animals were treated according to the guidelines of the
IACUC of the University of Pittsburgh. All the protocols
used were approved by the IACUC of the University
of Pittsburgh (#1002617). Rhesus macaques (Macaca
mulatta) were used for all non-human primate
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USDA guidelines for laboratory animals. Rhesus ma-
caques were anesthetized using 10-20 mg/kg ketamine
and vaccinated intramuscularly in the quadriceps and for-
mulated with ImjectW alum adjuvant (ImjectW Alum, Pierce
Biotechnology; Rockford, IL, USA). Vaccinations were com-
pleted at weeks 0, 4 and 8. Twelve animals were divided
into three (3) groups, four animals per group (Table 1). For
blood sample collection animals were anesthetized with a
mixture of ketamine/xylazine. Sera was then harvested and
stored at -80°C until needed.
Immune assays
Total anti-Envgp160 IgG was detected by enzyme-linked
immunosorbent assay (ELISA) using Concanavalin A
(50 μg/μl) per well as previously described [8]. End point
titer for assay was determined as the reciprocal of the di-
lution at which the optical density reading was above the
mean plus two standard deviations of naïve sera. For In
vitro neutralization, antisera were tested for the ability to
neutralize virus infection in vitro using TZM-Bl indicator
cells [8]. The sera dilution necessary to neutralize virus
was calculated by the following formula (relative light
units (RLU) of virus only-RLU of cell only)/2 + RLU cell
only. For assessment of T cell responses, NHP IFN-γ
ELISPOT was used to enumerate anti-Envgp160 specific
cellular responses. The number of anti-Envgp160 (SF162p3
and Con M) and Gag (SIVmac239) specific IFN-γ secreting
cells were determined using the non-human primate
enzyme-linked immunospot (ELISPOT) assay (R&D Sys-
tems, Minneapolis, MN, USA).
SHIV viral load determination
Real time PCR-based SIV viral detection assay was used to
determine the viral titers post-challenge as described in
[48]. cDNA (10 μl) generated by the RT-RCR reaction was
then used for PCR using the ABI 7000 Gene detection sys-
tem (Applied Bioscience, Carlsbad, California, USA).
Anti-CD8 cell depletion by antibody administration
All animals in the Con M group were depleted of CD8+ T
cells. The antibody M-T807R1 (NIH NHP Reagent Source,
Beth Israel Deacones Medical Center, Boston, MA, USA)
was administered subcutaneously (50 mg/Kg) on day 0
(Day 70 post infection). CD8+ T cell depletion was verified
using TruCOUNT tubes (BD Bioscience, San Jose, CA,
USA).
Statistical analysis
Statistical tests were performed using Graph Pad Prism
software. Statistical significance of antibody test was deter-
mined by two-way analysis of variance (ANOVA) followed
by the Bonferroni’s post-hoc test. Post-test was used toanalyze differences between the vaccine groups. Signifi-
cance was determined to be a p<0.05.
Additional file
Additional file 1: Figure S1. Representative sensograms of IgG b12
SPR data. SPR binding isotherms detailing the interaction of each
recombinant trimeric Envgp140 with the monoclonal antibody b12 are
displayed. Indicated concentrations of each Envgp140 were flowed over
captured b12 at 37°C on CM5 chips as detailed in Materials and Methods.
Association rates, dissociation rates, and affinity constants were calculated
with BIA evaluation 4.1.1 software (GE/Biacore AB, Uppsala, Sweden). A,
ConA; B, ConB; C, ConC; D, Con M; E, ConE; F, ADA; G, PV0.04; H, R2; I,
SC42; and J, YU2. Black lines are determined 1:1 Langmuir kinetic fits. RU,
resonance units.
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